BNTX · Nasdaq · CIK 0001776985

BioNTech SE

BioNTech SE’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of EUR 2.9B and net income of -EUR 1.1B, according to its XBRL data on EDGAR. Its EDGAR record lists 20 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
EUR 2.9B
Net income, FY2025
-EUR 1.1B
Form 4 filings on record, past 12 months
20

Company overview

Legal name (as filed)
BioNTech SE
Ticker
BNTX
SEC Central Index Key (CIK)
0001776985
Business address
MAINZ, Germany
State or country of incorporation
Germany
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#555 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from BioNTech SE’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
EUR 19.0BFY2021EUR 17.3BFY2022EUR 3.8BFY2023EUR 2.8BFY2024EUR 2.9BFY2025
Net income
EUR 10.3BFY2021EUR 9.4BFY2022EUR 930.3MFY2023-EUR 665.3MFY2024-EUR 1.1BFY2025
BNTX annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
RevenueEUR 19.0BEUR 17.3BEUR 3.8BEUR 2.8BEUR 2.9B
Net incomeEUR 10.3BEUR 9.4BEUR 930.3M-EUR 665.3M-EUR 1.1B
Diluted EPSEUR 39.63EUR 37.77EUR 3.83-EUR 2.77-EUR 4.70
Total assetsEUR 15.8BEUR 23.3BEUR 23.0BEUR 22.5BEUR 22.0B
Cash and equivalentsEUR 1.1BEUR 1.3BEUR 453.1MEUR 450.0MEUR 7.7B

XBRL tags used: revenue = RevenueFromContractsWithCustomers; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

BNTX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 10, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about BioNTech SE, by form type:

6-K ×184 ×163 ×2SCHEDULE 13G/A ×2144 ×120-F/A ×1
BNTX recent filings
FiledFormWhat it isOriginal
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index
Oct 22, 20266-KReport of a foreign private issuer· period Oct 22, 2026Document · Index
Oct 19, 20266-KReport of a foreign private issuer· period Oct 19, 2026Document · Index
Oct 13, 20266-KReport of a foreign private issuer· period Oct 13, 2026Document · Index
Oct 9, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 8, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 7, 2026Document · Index
Oct 6, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Sep 30, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 29, 2026Document · Index
Sep 28, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 25, 2026Document · Index
Sep 24, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 23, 2026Document · Index
Sep 22, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 18, 20266-KReport of a foreign private issuer· period Sep 18, 2026Document · Index
Sep 16, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026Document · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 11, 2026Document · Index
Sep 14, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 9, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 8, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 3, 2026Document · Index
Sep 3, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 28, 20266-KReport of a foreign private issuer· period Aug 28, 2026Document · Index
Aug 27, 20266-KReport of a foreign private issuer· period Aug 27, 2026Document · Index
Aug 20, 20266-KReport of a foreign private issuer· period Aug 20, 2026Document · Index
Aug 4, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Aug 4, 20266-KReport of a foreign private issuer· period Aug 4, 2026Document · Index
Aug 3, 20266-KReport of a foreign private issuer· period Aug 3, 2026Document · Index
Jul 30, 202620-F/AAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Jul 29, 20266-KReport of a foreign private issuer· period Jul 29, 2026Document · Index
Jun 26, 20263Initial statement of beneficial ownership· period Jun 26, 2026Document · Index
Jun 26, 20263Initial statement of beneficial ownership· period Jun 26, 2026Document · Index
Jun 8, 20266-KReport of a foreign private issuer· period Jun 8, 2026Document · Index
Jun 1, 20266-KReport of a foreign private issuer· period Jun 1, 2026Document · Index
May 22, 20266-KReport of a foreign private issuer· period May 22, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 20266-KReport of a foreign private issuer· period May 15, 2026Document · Index
May 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 13, 20264Statement of changes in beneficial ownership (insider trade)· period May 12, 2026Document · Index
May 13, 20264Statement of changes in beneficial ownership (insider trade)· period May 12, 2026Document · Index

Insider filing activity

20 Form 4 filings appear in BioNTech SE’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001776985 and XBRL company facts. BioNTech SE on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.